GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Syneron Medical Ltd. (ELOS) [hlAlert]

Rating:
Outperform
ELOS
down 4.00 %

Syneron Medical Ltd. (ELOS) rated Outperform with price target $16 by Oppenheimer

Posted on: Friday,  Sep 18, 2009  8:25 AM ET by Oppenheimer

Oppenheimer rated Outperform Syneron Medical Ltd. (NASDAQ: ELOS) on 09/18/2009, when the stock price was $9.74. Since
then, Syneron Medical Ltd. has lost 4.00% as of 11/11/2015's recent price of $9.35.
If you would have followed this Oppenheimer's recommendation on ELOS, you would have lost 4% of your investment in 2245 days.

Syneron Medical Ltd. manufactures and distributes medical aesthetic devices that are powered by the proprietary, patented ELOS combined-energy technology of Bi-Polar Radio Frequency and Light. The Company's innovative ELOS technology provides the foundation for highly effective, safe and cost-effective systems that enable physicians to provide advanced solutions for a broad range of medical-aesthetic applications.

OppenheimerFunds, Inc. has been helping investors achieve their financial goals since 1960. We are one of the nation's largest and most respected asset management companies. At OppenheimerFunds, we believe that in order for you to reach your financial goals, your investments must perform. That is why investment excellence—over the long term and across the range of our products—is our highest priority. OppenheimerFunds and its controlled affiliates offer a broad range of products and services to individuals, corporations and institutions, including mutual funds, separately managed accounts, investment management for institutions, hedge fund products, qualified retirement plans and subadvisory investment-management services.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
9/18/2009 8:25 AM Buy
None
9.74 16.00
as of 12/31/2009
1 Week up  2.90 %
1 Month up  2.60 %
3 Months down  -10.07 %
1 YTD up  5.33 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy